PT - JOURNAL ARTICLE AU - Linneberg, A AU - Kampmann, FB AU - Israelsen, SB AU - Andersen, LR AU - Jørgensen, HL AU - Sandholt, H AU - Jørgensen, NR AU - Thysen, SM AU - Benfield, T TI - Low vitamin K status predicts mortality in a cohort of 138 hospitalized patients with COVID-19 AID - 10.1101/2020.12.21.20248613 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.21.20248613 4099 - http://medrxiv.org/content/early/2020/12/23/2020.12.21.20248613.short 4100 - http://medrxiv.org/content/early/2020/12/23/2020.12.21.20248613.full AB - It has recently been hypothesised that Vitamin K could play a role in COVID-19. We aimed to test the hypothesis that low vitamin K status is a common characteristic of patients hospitalized with COVID-19 compared to population controls; and that low vitamin K status predicts mortality in COVID-19 patients. In a cohort of 138 COVID-19 patients and 140 population controls, we measured plasma dephosphorylated-uncarboxylated Matrix Gla Protein (dp-ucMGP), which reflects the functional Vitamin K status in peripheral tissue. Fourty-three patients died within 90-days from admission. In patients, levels of dp-ucMGP differed significantly between survivors (mean 877; 95% CI: 778; 995) and non-survivors (mean 1445; 95% CI: 1148; 1820). Furthermore, levels of dp-ucMGP (pmol/L) were considerably higher in patients (mean 1022; 95% CI: 912; 1151) compared to controls (mean 509; 95% CI: 485; 540). Cox regression survival analysis showed that increasing levels of dp-ucMGP (reflecting low Vitamin K status) were associated with higher mortality risk (sex- and age-adjusted hazard ratio per doubling of dp-ucMGP was 1.50, 95% CI: 1.03; 2.18). In conclusion, we found that low Vitamin K status predicted mortality in patients with COVID-19 supporting a potential role of Vitamin K in COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe present study was funded by the participating institutions and a Steno Collaborative Grant 2019 from the Novo Nordisk Foundation (0058130). The IDS-iSYS InaKtif MGP immunoassay kits were provided by Immunodiagnostic Systems Limited, Boldon, UK.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Amager Hvidovre Hospital (Hvidovre) COVID-19 cohort was approved by the Danish Patient Safety Authority (record no. 31-1521-309) and the Regional Data Protection Center (record no. P-2020-492). The current analysis and measurements of dp-ucMGP in stored plasma samples from the biobank were approved by the Ethical Committee of the Capital Region of Denmark (record no. H-20047597).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are protected by Danish Data Protection Regulations. Requests for data access can be made to the corresponding author, but must be approved by Danish data protection authorities.